Long Cast Advisers, an independent registered investment adviser, released its Q2 2026 investor letter. A copy can be downloaded here. The firm reported strong earnings in the second quarter, with results improving 20%, bringing year-to-date returns to +19%. While performance trailed the Russell 2000 and iShares US MicroCap ETF, it remained well ahead of the iShares SmallCap EAFE (ex-N. Am) ETF. Since inception in 2015, ****** ulative returns stand at 343% (15% CAGR), reflecting the firm's strategy of concentrated, patient investments in small and micro‑cap companies. The firm remains cautious in this environment, emphasizing patience and endurance while avoiding margin and volatility. In addition, please check the firm's top five holdings to know its best picks in 2026.
In its Q2 2026 investor letter, Long Cast Advisers highlighted NRC Health (NASDAQ:NRC). NRC Health (NASDAQ:NRC) provides ****** ytics and insights to enhance the patient and employee experience of healthcare organizations in the United States. NRC Health (NASDAQ:NRC) was formerly known as National Research Corporation and changed its name in April 2026. On August 7, 2026, NRC Health (NASDAQ:NRC) closed at $20.34 per share, reflecting a market capitalization of $449.9 million and a year‑to‑date gain of 9.30%. NRC Health (NASDAQ:NRC) posted a one‑month return of ‑6.02%, while its shares gained 35.95% over the past 52 weeks.
Long Cast Advisers stated the following regarding NRC Health (NASDAQ:NRC) in its Q2 2026 investor letter:
"On NRC Health (NASDAQ:NRC), our newest investment, I discussed the company's evolution from owner / operator to professionally led management team, and the expected benefits from putting a growth focused, incentivized and entrepreneurial executive suite behind this strong and recognizable brand, in a business with strong FCF generation and in a market where the two leading competitors just merged in a PE backed $6.5B deal.
Quantitative evidence that supports our optimism includes the recently announced largest contract in company history, leading to the highest 12-mos backlog in history. Deferred revs are also growing and this typically leads sales. Furthermore, management indicated that the second year of the aforementioned contract is materially larger than the first, which infers that in one year's time, 12-mos backlog could be even larger, and with capacity to do more. We continue to add opportunistically."
#NASDAQ #letter #investment
In its Q2 2026 investor letter, Long Cast Advisers highlighted NRC Health (NASDAQ:NRC). NRC Health (NASDAQ:NRC) provides ****** ytics and insights to enhance the patient and employee experience of healthcare organizations in the United States. NRC Health (NASDAQ:NRC) was formerly known as National Research Corporation and changed its name in April 2026. On August 7, 2026, NRC Health (NASDAQ:NRC) closed at $20.34 per share, reflecting a market capitalization of $449.9 million and a year‑to‑date gain of 9.30%. NRC Health (NASDAQ:NRC) posted a one‑month return of ‑6.02%, while its shares gained 35.95% over the past 52 weeks.
Long Cast Advisers stated the following regarding NRC Health (NASDAQ:NRC) in its Q2 2026 investor letter:
"On NRC Health (NASDAQ:NRC), our newest investment, I discussed the company's evolution from owner / operator to professionally led management team, and the expected benefits from putting a growth focused, incentivized and entrepreneurial executive suite behind this strong and recognizable brand, in a business with strong FCF generation and in a market where the two leading competitors just merged in a PE backed $6.5B deal.
Quantitative evidence that supports our optimism includes the recently announced largest contract in company history, leading to the highest 12-mos backlog in history. Deferred revs are also growing and this typically leads sales. Furthermore, management indicated that the second year of the aforementioned contract is materially larger than the first, which infers that in one year's time, 12-mos backlog could be even larger, and with capacity to do more. We continue to add opportunistically."
#NASDAQ #letter #investment
3 months ago
